BRPI0615180A2 - método para intensificar a quimioterapia - Google Patents

método para intensificar a quimioterapia Download PDF

Info

Publication number
BRPI0615180A2
BRPI0615180A2 BRPI0615180-9A BRPI0615180A BRPI0615180A2 BR PI0615180 A2 BRPI0615180 A2 BR PI0615180A2 BR PI0615180 A BRPI0615180 A BR PI0615180A BR PI0615180 A2 BRPI0615180 A2 BR PI0615180A2
Authority
BR
Brazil
Prior art keywords
formula
ring
optionally substituted
alkyl
substituted
Prior art date
Application number
BRPI0615180-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Gary J Bridger
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37758501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0615180(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0615180A2 publication Critical patent/BRPI0615180A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0615180-9A 2005-08-19 2006-08-21 método para intensificar a quimioterapia BRPI0615180A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70997805P 2005-08-19 2005-08-19
US60/709,978 2005-08-19
US73473605P 2005-11-08 2005-11-08
US60/734,736 2005-11-08
PCT/US2006/032668 WO2007022523A2 (en) 2005-08-19 2006-08-21 Methods to enhance chemotherapy

Publications (1)

Publication Number Publication Date
BRPI0615180A2 true BRPI0615180A2 (pt) 2011-05-03

Family

ID=37758501

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615180-9A BRPI0615180A2 (pt) 2005-08-19 2006-08-21 método para intensificar a quimioterapia

Country Status (9)

Country Link
US (1) US20070043012A1 (cg-RX-API-DMAC7.html)
EP (1) EP1951046B1 (cg-RX-API-DMAC7.html)
JP (3) JP2009504788A (cg-RX-API-DMAC7.html)
CN (1) CN101365336B (cg-RX-API-DMAC7.html)
AU (1) AU2006280945A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0615180A2 (cg-RX-API-DMAC7.html)
CA (1) CA2619828A1 (cg-RX-API-DMAC7.html)
IL (1) IL189599A0 (cg-RX-API-DMAC7.html)
WO (1) WO2007022523A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) * 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
EP3011961B1 (en) * 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
WO2008109076A1 (en) * 2007-03-02 2008-09-12 Oxigene, Inc. Methods for enhancing the efficacy of vascular disrupting agents
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
US20110207814A1 (en) * 2009-12-23 2011-08-25 Pranela Rameshwar Combination Therapy for Breast Cancer Treatment
SG188220A1 (en) * 2010-09-09 2013-04-30 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CN105163749B (zh) 2013-03-24 2018-03-27 拜欧肯治疗有限公司 治疗骨髓性白血病的方法
EP3062809B1 (en) 2013-10-31 2020-07-08 Biokine Therapeutics Ltd. A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
JP2017508005A (ja) * 2014-02-19 2017-03-23 マイクロコンスタンツ チャイナ インク ケモカイン受容体アンタゴニストおよびその併用療法
KR101759688B1 (ko) * 2015-01-16 2017-07-20 서울대학교산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
WO2016114634A2 (ko) * 2015-01-16 2016-07-21 서울대학교 산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
MX2017013668A (es) * 2015-04-25 2018-07-06 Massachusetts Gen Hospital Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
AU2016324303A1 (en) * 2015-09-18 2018-04-26 The General Hospital Corporation Dba Massachusetts General Hospital Modified T-cells having anti-fugetactic properties and uses thereof
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN109069426B (zh) * 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
CA3066778A1 (en) * 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020065647A1 (en) 2018-09-25 2020-04-02 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
TWI781469B (zh) * 2020-10-27 2022-10-21 行政院原子能委員會核能研究所 複合物、造影劑及治療與cxcr4接受體相關疾病的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005204A (en) * 1973-03-23 1977-01-25 Burroughs Wellcome Co. Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP1244648B1 (en) * 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
KR20030034184A (ko) 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
RU2289581C2 (ru) 2000-09-15 2006-12-20 Анормед, Инк. Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
CA2431611A1 (en) 2001-01-23 2002-08-01 P&G-Clairol, Inc. Primary intermediates for oxidative coloration of hair
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1608318A4 (en) 2003-03-27 2009-07-29 Univ Emory CXCR4 ANTAGONISTS AND METHOD OF USE
US20040202935A1 (en) 2003-04-08 2004-10-14 Jeremy Barker Cathode active material with increased alkali/metal content and method of making same
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆/幹細胞を動員するためのケモカインの組み合わせ
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
AU2006340074A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration

Also Published As

Publication number Publication date
EP1951046A4 (en) 2010-03-17
CN101365336B (zh) 2013-05-29
AU2006280945A1 (en) 2007-02-22
US20070043012A1 (en) 2007-02-22
EP1951046A2 (en) 2008-08-06
WO2007022523A2 (en) 2007-02-22
JP2009504788A (ja) 2009-02-05
IL189599A0 (en) 2008-08-07
CA2619828A1 (en) 2007-02-22
JP2013107903A (ja) 2013-06-06
CN101365336A (zh) 2009-02-11
WO2007022523A3 (en) 2007-11-22
JP2013231086A (ja) 2013-11-14
EP1951046B1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
CN101365336B (zh) 增强化疗的方法
BRPI0715393A2 (pt) terapia de combinaÇço
BRPI0714799A2 (pt) terapia de combinaÇço
CN1561208B (zh) 活化祖细胞/干细胞的方法
JP2008509928A (ja) 前駆/幹細胞を動員するためのケモカインの組み合わせ
JP2006526646A (ja) 前駆細胞/幹細胞を動員するための方法
BRPI0810911A2 (pt) Compostos com atividade anticâncer
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
MX2008002374A (en) Methods to enhancechemotherapy
ES2497092T3 (es) Procedimientos para el aumento del flujo sanguíneo y/o la estimulación de la regeneración de tejidos
MX2007001802A (en) Chemokine combinations to mobilize progenitor/stem cells
JPWO1992015296A1 (ja) 腎疾患治療剤

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2268 DE 24/06/2014.